Frank H. Laukien, Ph.D.

Frank H. Laukien, Ph.D.

Chairman, President and Chief Executive OfficeratBruker· In proxies 2021–2025

Pay in FY2025-15% from the year before · Bruker stock -19.6% the same year

Frank H. Laukien, Ph.D. was paid $4.7M in FY2025 (Dec), down 15%. Bruker stock fell 19.6% that year.

Pay$100 in the stock at the end of FY20 → $87
Pay is from the Summary Compensation Table of each Bruker proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. BrukerPublic company · 5 yr
    • Chairman, President and Chief Executive Officer2021 – Present · 5 yrStock in role +15%
  2. Terrain Biosciences, Inc.Public company
    • Director? – PresentNo stock prices for these years
  3. Tome BiosciencesPublic company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?